Browse the evidence

Participants demonstrated a 36.5% increase in composite load lifted across compound exercises.

Strength training protocols can effectively enhance lifting capacity in breast cancer survivors.

At 1-month follow-up, patients showed a 22.3 percent decrease in average fat tissue and a 21.5 percent increase in muscle mass.

The HIFEM+RF procedure can effectively reduce fat and increase muscle in the upper arms.

At 3-month follow-up, there was an average decrease in fat tissue by 25.5 percent and an average increase in muscle mass by 23.9 percent.

The HIFEM+RF procedure continues to show effectiveness in fat reduction and muscle gain over time.

Increasing weekly sets may offer additional benefits for 1RM and vastus lateralis cross-sectional area.

Practitioners may consider increasing resistance training volume to enhance strength and muscle size.

All groups demonstrated improvements in the measured outcomes.

Resistance training is effective for improving strength and muscle outcomes in females.

Seated knee extension exercises produced approximately 8% greater peak torque and work output compared to supine knee extension exercises.

Practitioners may consider seated knee extension exercises for improved performance in strength and work output.

Muscle thickness of the middle rectus femoris and proximal vastus lateralis increased significantly with no difference between exercise variations.

Both seated and supine positions can lead to muscle swelling, which may be beneficial for hypertrophy.

Muscle thickness of the middle vastus lateralis increased only after the seated knee extension exercise.

Seated knee extensions may be more effective for targeting the vastus lateralis for muscle growth.

Kin teams lost more weight after the intervention in the gamification and gamification with PCP sharing arms.

Practitioners may consider the social dynamics of participant pairs when implementing weight loss interventions.

Married teams lost the most weight across all 3 arms and kept it off following the intervention.

Understanding the characteristics of successful participants can inform future intervention designs.

A 20-min walk post-breakfast reduces postprandial hyperglycaemia in Early (0700 h) and Delayed (1200 h) conditions.

Encouraging a short walk after breakfast may help manage blood sugar levels in patients with type 2 diabetes.

Delaying breakfast to 0930 or 1200 h is a low-cost strategy to improve glycaemic management in people with type 2 diabetes.

Healthcare providers can suggest delaying breakfast as a simple and cost-effective method for improving glycaemic control.

GLP-1 medicines reduce food intake, body weight, insulin resistance and inflammation.

GLP-1 medicines can be considered for managing weight and metabolic health in patients with type 2 diabetes and obesity.

Incretin mimetics, including glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists, are first-line treatment options for type 2 diabetes and obesity.

Healthcare professionals should consider these agents as primary treatment options for managing type 2 diabetes and obesity.

Semaglutide demonstrated superior efficacy with mean HbA1c reduction of 1.45% and weight loss of 1.44 kg.

Semaglutide is the most effective GLP-1 receptor agonist for improving glycemic control and promoting weight loss in T2DM patients.

Emerging oral therapies could complement or serve as alternatives to approved injectable treatments for long-term weight management.

Practitioners should consider these oral therapies as viable options alongside injectables.

Preconception weight optimization in women with obesity is important to reduce maternal and fetal risks.

Practitioners should prioritize weight management in women with obesity planning for pregnancy.

Average A1c decreased from 8.9% ± 1.3% to 7.6% ± 1.5% over 6 months (P < 0.001).

Clinicians may expect improvements in glycemic control with semaglutide in T2DM patients.

Body weight decreased from 123.9 ± 23.5 kg to 118.9 ± 22.9 kg over 6 months (P < 0.001).

Clinicians may observe weight loss in T2DM patients treated with semaglutide.

Modern dual and triple agonists achieve surgical-level metabolic benefits, redefining diabetes and obesity care.

These agonists may offer new treatment options for diabetes and obesity.

Newer anti-obesity medications such as semaglutide and tirzepatide have shown greater than 15% reduction in baseline weight.

Practitioners should consider these medications for patients seeking significant weight loss.

Weight loss of more than 10% may reduce obesity-associated cancer incidence.

Encouraging significant weight loss may be a viable strategy for reducing cancer risk in obese patients.

GLP-1 agonists are associated with favorable hemoglobin A1C levels and weight loss in type 1 diabetic patients.

GLP-1 agonists may be recommended for type 1 diabetes patients aiming for better glycemic control and weight management.

Tirzepatide treatment shows a potent glucose-lowering effect and promotes weight loss with minimal GI adverse effects.

Tirzepatide may be considered for patients needing effective glucose control and weight loss with fewer gastrointestinal side effects.